Culbertson A N & Co. Inc. reduced its stake in shares of Clorox Co (NYSE:CLX) by 5.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,374 shares of the company’s stock after selling 440 shares during the quarter. Culbertson A N & Co. Inc.’s holdings in Clorox were worth $1,286,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Marshall Wace North America L.P. acquired a new position in shares of Clorox during the first quarter worth approximately $65,000. Bernardo Wealth Planning LLC lifted its stake in shares of Clorox by 13.2% during the second quarter. Bernardo Wealth Planning LLC now owns 1,541 shares of the company’s stock valued at $236,000 after acquiring an additional 180 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Clorox during the second quarter valued at $268,000. Victory Capital Management Inc. lifted its stake in shares of Clorox by 90.5% during the second quarter. Victory Capital Management Inc. now owns 52,068 shares of the company’s stock valued at $7,972,000 after acquiring an additional 24,732 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Clorox by 8.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 632,461 shares of the company’s stock valued at $96,836,000 after acquiring an additional 51,252 shares during the period. Institutional investors and hedge funds own 77.94% of the company’s stock.
CLX has been the topic of several analyst reports. JPMorgan Chase & Co. reissued an “underweight” rating and issued a $137.00 target price (down previously from $143.00) on shares of Clorox in a research note on Thursday, October 3rd. Credit Suisse Group cut their target price on Clorox from $172.00 to $168.00 and set an “outperform” rating on the stock in a research note on Thursday, October 3rd. Bank of America cut their target price on Clorox from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, October 3rd. Deutsche Bank increased their target price on Clorox from $145.00 to $147.00 and gave the company a “hold” rating in a research note on Thursday, December 12th. Finally, UBS Group cut their target price on Clorox from $128.00 to $125.00 and set a “sell” rating on the stock in a research note on Thursday, October 3rd. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $152.17.
In related news, SVP Andrew J. Mowery sold 5,648 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $146.29, for a total transaction of $826,245.92. Following the sale, the senior vice president now owns 15,920 shares in the company, valued at approximately $2,328,936.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Denise Garner sold 725 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $146.34, for a total value of $106,096.50. Following the sale, the senior vice president now owns 5,805 shares in the company, valued at approximately $849,503.70. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.
Shares of NYSE:CLX traded up $2.88 during mid-day trading on Monday, reaching $161.16. 1,694,464 shares of the stock were exchanged, compared to its average volume of 730,032. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 4.69. The company has a market cap of $19.86 billion, a P/E ratio of 25.54, a P/E/G ratio of 5.09 and a beta of 0.39. Clorox Co has a one year low of $143.58 and a one year high of $166.90. The stock’s 50 day simple moving average is $153.75 and its 200-day simple moving average is $153.99.
Clorox (NYSE:CLX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.54 by $0.05. The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.51 billion. Clorox had a return on equity of 123.56% and a net margin of 13.20%. Clorox’s quarterly revenue was down 3.6% on a year-over-year basis. During the same period last year, the company earned $1.62 earnings per share. Analysts anticipate that Clorox Co will post 6.14 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 29th will be given a $1.06 dividend. The ex-dividend date of this dividend is Tuesday, January 28th. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.63%. Clorox’s payout ratio is 67.09%.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Recommended Story: What is a capital gain?
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.